Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of sitaxsentan in pulmonary arterial hypertension
2008-005885-30Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sitaxsentan 100 mg with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance at Week 12. Started Dec 2008; status: terminated.
02
Drugs
sitaxsentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2008-005885-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005885-30.